Allogene Therapeutics, Inc. ALLO R2K

Healthcare · Biotechnology · United States

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Market & Price

Market Cap

$748.99M

Current Price

$2.17

High / Low (52W)

$3.06 / $1.03

Beta

0.46

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$1.14

Price to Book

1.91

P/S

EV/EBITDA

-3.21

Dividend Yield

Profitability & Returns

ROCE

-49.51%

ROE

-52.32%

ROA

-25.97%

Profit Margin

0.00%

Op Margin

0.00%

EPS (Latest Qtr)

$-0.18

EPS (TTM)

$-0.77

Balance Sheet & Liquidity

Debt/Equity

0.29

Quick Ratio

9.47

Current Ratio

9.65

Debt

$81.05M

Total Assets

$415.90M

Current Assets

$257.75M

Working Capital

$225.24M

Ownership

Promoter Holding

11.05%

Chg in Prom Hold

0.24%

FII / Inst Holding

52.87%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$563.15M

Total Revenue (TTM)

EBITDA

$-175.70M

Free Cash Flow

$-69.94M

Operating Cash Flow

$-109.23M

Shares Outstanding

345.15M

Gross Margin

0.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-33.33%

Profit 5Y

14.64%

Revenue (YoY)

Earnings (YoY)

PROS

Profit CAGR of 14.6% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -33.3% CAGR over 5 years.
Trading 29.1% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ALLO Allogene Therapeutics, Inc. R2K	2.17	-	$748.99M	-	-49.51%	-52.32%	-33.33%	14.64%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	0	0	0	38.34M	44.00K	49.00K	39.00K	64.00K	27.00K	30.00K	22.00K	22.00K	22.00K	0	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65.19M	54.44M	44.90M	42.40M	46.09M
Operating Income	-2.60M	-135.01M	-22.19M	-33.05M	-36.46M	-45.96M	-55.01M	-64.58M	-57.68M	-63.16M	-68.04M	-33.20M	-71.03M	-77.67M	-80.01M	-76.62M	-82.51M	-99.09M	-80.54M	-63.00M	-69.50M	-71.43M	-	-	-65.19M	-54.44M	-44.90M	-42.40M	-46.09M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-56.48M	-47.57M	-37.96M	-35.44M	-39.44M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	150.00K	268.00K	344.00K	313.00K	300.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-59.73M	-50.94M	-41.40M	-38.81M	-42.61M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-2.60M	-134.90M	-43.50M	-30.51M	-31.59M	-41.24M	-50.73M	-61.03M	-54.48M	-60.97M	-66.20M	-33.02M	-70.94M	-78.19M	-78.61M	-80.29M	-84.24M	-99.97M	-79.23M	-62.29M	-65.00M	-66.36M	-	-	-59.73M	-50.94M	-41.40M	-38.81M	-42.61M
Diluted EPS	-	-	-	-	-	-	-	-	-	-0.53	-0.52	-0.25	-0.53	-0.57	-0.56	-0.56	-0.59	-0.69	-0.54	-0.37	-0.38	-0.35	-	-	-0.28	-0.23	-0.19	-0.17	-0.18
R&D Expense	-	122.49M	10.87M	-	23.40M	31.77M	39.99M	-	42.04M	47.30M	51.42M	55.18M	52.29M	58.72M	60.16M	57.17M	63.64M	80.24M	62.04M	45.98M	52.26M	50.35M	44.71M	-	50.20M	40.16M	31.16M	-	32.00M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	0	0	-	156.00K	95.00K	22.00K	0
Cost of Revenue	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	335.69M	314.59M	257.50M	206.93M
Operating Income	-192.84M	-202.01M	-258.24M	-	-335.54M	-314.49M	-257.48M	-206.93M
EBITDA	-	-	-	-	-321.24M	-313.07M	-243.33M	-177.45M
Interest Expense	-	-	-	-	-	0	181.00K	1.07M
Pretax Income	-	-	-	-	-340.41M	-327.26M	-257.15M	-190.89M
Tax Provision	-	-	-	0	-	0	443.00K	0
Net Income	-211.50M	-184.59M	-250.22M	-	-340.41M	-327.26M	-257.59M	-190.89M
Diluted EPS	-	-1.83	-2.08	-1.89	-2.32	-2.09	-1.32	-
R&D Expense	151.86M	144.53M	192.99M	220.18M	256.39M	242.91M	192.30M	150.15M

Compounded Sales Growth

5 Years:	-33.33%
1 Year:	-

Compounded Profit Growth

5 Years:	14.64%
1 Year:	-

Stock Price Performance

1 Year:	+85.47%
6 Months:	+59.56%
3 Months:	-21.94%
1 Month:	+2.84%

Balance Sheet (Annual)

Figures in USD.

Metric	Nov 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	773.86M	717.80M	1.23B	-	978.09M	955.62M	894.48M	821.58M	750.13M	773.01M	713.41M	642.84M	548.71M	415.90M
Current Assets	-	-	-	-	-	-	-	-	-	528.82M	-	-	-	459.12M	303.39M	257.75M
Cash & Equivalents	-	-	92.43M	175.13M	183.35M	-	84.51M	96.04M	74.36M	61.90M	109.93M	154.76M	69.25M	83.16M	75.22M	51.69M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	2.00K	70.69M	88.78M	148.21M	-	112.82M	149.14M	151.08M	154.70M	158.12M	151.60M	132.78M	130.60M	126.53M	123.36M
Current Liabilities	-	2.00K	29.46M	33.08M	94.32M	-	36.62M	44.18M	48.08M	53.73M	59.40M	54.58M	37.49M	37.08M	35.52M	32.51M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	101.12M	-	-	-	95.12M	90.76M	83.25M
Total Equity	0	-2.00K	703.16M	629.02M	1.01B	-	865.27M	806.48M	743.40M	666.88M	592.01M	621.41M	580.63M	512.23M	422.18M	292.54M
Shares Outstanding	-	-	-	-	-	-	-	-	-	144.44M	-	-	-	168.64M	212.21M	229.41M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-44.65M	-137.35M	-115.09M	-	-220.52M	-237.73M	-200.30M	-149.25M
Investing Cash Flow	-632.80M	164.08M	-505.12M	-	106.16M	163.29M	75.69M	95.56M
Financing Cash Flow	771.18M	58.96M	633.59M	-	2.95M	95.69M	116.67M	30.16M
Capital Expenditure	-3.23M	-50.79M	-65.96M	-	-5.19M	-1.52M	-694.00K	-386.00K
Free Cash Flow	-47.89M	-188.14M	-181.05M	-	-225.71M	-239.25M	-200.99M	-149.63M
Net Change in Cash	-	-	-	-	-111.41M	21.25M	-7.94M	-23.53M

Ratios (Annual)

Figures in %.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-215,087.2%	-331,044.2%	-1,170,372.7%	-
Net Margin %	-	-	-	-	-218,214.1%	-344,489.5%	-1,170,863.6%	-
ROE %	-30.1%	-29.3%	-24.7%	-	-51.0%	-63.9%	-61.0%	-65.3%
ROCE %	-25.9%	-29.5%	-22.8%	-	-43.7%	-51.9%	-50.2%	-54.0%

Shareholding Pattern

Insiders

11.05%

Institutions

52.87%

Public Float

59.44%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Pfizer Inc	6.38%	22.03M	$47.81M
2	Blackrock Inc.	5.53%	19.09M	$41.43M
3	TPG GP A, LLC	5.42%	18.72M	$40.61M
4	State Street Corporation	2.51%	8.66M	$18.79M
5	Primecap Management Company	2.43%	8.38M	$18.18M
6	Vanguard Capital Management LLC	2.01%	6.92M	$15.02M
7	Citadel Advisors Llc	1.97%	6.79M	$14.74M
8	Price (T.Rowe) Associates Inc	1.56%	5.38M	$11.68M
9	Two Sigma Investments, LP	1.56%	5.38M	$11.66M
10	Geode Capital Management, LLC	1.19%	4.12M	$8.95M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALLO

No recent headlines available.

ALLO · Healthcare